Absence of mutagenic activity of WHR-1142A, lidamidine hydrochloride, in 4 short-term tests for mutagenic/carcinogenic potential.
WHR-1142A, lidamidine hydrochloride, an antidiarrhoeal agent, was tested for possible mutagenic/carcinogenic activity in the Ames Salmonella typhimurium/metabolic activation test, the micronucleus test, by analysis of metaphase chromosomes obtained from human lymphocytes grown in culture and in a cell transformation assay. No evidence of mutagenic/carcinogenic activity due to WHR-1142A, lidamidine hydrochloride, was found in any of the 4 tests.
D000818:Animals; D001711:Biotransformation; D002460:Cell Line; D002467:Cell Nucleus / Q000187:drug effects*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002869:Chromosome Aberrations; D006224:Cricetinae; D004912:Erythrocytes / Q000187:drug effects; D006801:Humans; D007668:Kidney; D008214:Lymphocytes / Q000187:drug effects; D008647:Mesocricetus; D051379:Mice; D009152:Mutagenicity Tests; D009153:Mutagens; D010671:Phenylurea Compounds / Q000494:pharmacology*; D051381:Rats; D012486:Salmonella typhimurium / Q000187:drug effects*
D009153:Mutagens; D010671:Phenylurea Compounds; C020918:lidamidine